Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.44 |
| ▸ | DPP4 | P27487 | 6/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24520190 | 1.00 | SLC7A5 (0.46) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24520194 | 1.00 | SLC7A5 (0.46) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL7058398 | 0.98 | SLC7A5 (0.44) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 | |
| Bromide SCHEMBL5466774 | 0.96 | SLC7A5 (0.46) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 | |
| Bromide SCHEMBL5466773 | 0.96 | SLC7A5 (0.46) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7055890 | 0.96 | SLC7A5 (0.46) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL7053307 | 0.94 | SLC7A5 (0.44) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1417103 | 0.91 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1DPP4 | |
| SCHEMBL27620408 | 0.88 | SLC7A5 (0.43) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24548511 | 0.83 | SLC7A5 (0.43) | SLC7A5EPHX1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7833986-B2 | Anti-inflammatory peptides | SALPEP BIOTECHNOLOGY INC. (CA) | 2010-11-16 | — | — | US | claimed |
| EP-2072524-A2 | Anti-inflammatory peptides | Salpep Biotechnology, Inc. (CA) | 2009-06-24 | — | — | EP | claimed |
| US-20070054865-A1 | Anti-inflammatory peptides | AIM THERAPEUTICS INC. (CA) | 2007-03-08 | — | — | US | claimed |
| US-7153835-B2 | Anti-inflammatory peptides | SALPEP BIOTECHNOLOGY, INC. (CA) | 2006-12-26 | — | — | US | claimed |
| EP-1474439-A2 | DIPEPTIDES AND TRIPEPTIDES WITH ANTI-INFLAMMATORY ACTIVITY | Salpep Biotechnology Inc. (CA) | 2004-11-10 | — | — | EP | claimed |
| US-20030229145-A1 | Pain treatment methods and compositions | GRUENENTHAL GMBH (DE) | 2003-12-11 | — | — | US | claimed |
| US-20030195141-A1 | Anti-inflammatory peptides | AIM THERAPEUTICS INC. (CA) | 2003-10-16 | — | — | US | claimed |
| WO-2003066670-A2 | DIPEPTIDES AND TRIPEPTIDES WITH ANTI-INFLAMMATORY ACTIVITY | SALPEP BIOTECHNOLOGY INC. (CA) | 2003-08-14 | — | — | WO | claimed |
| EP-1326826-A1 | USE OF AMINO ACIDS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2003-07-16 | — | — | EP | claimed |
| WO-2002030871-A1 | USE OF AMINO ACIDS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | claimed |
| WO-2022129630-A1 | G PROTEIN PEPTIDOMIMETICS | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2022-06-23 | — | — | WO | disclosed |
| EP-4015529-A1 | G PROTEIN PEPTIDOMIMETICS | Vrije Universiteit Brussel (BE) | 2022-06-22 | — | — | EP | disclosed |
| US-7833986-B2 | Anti-inflammatory peptides | SALPEP BIOTECHNOLOGY INC. (CA) | 2010-11-16 | — | — | US | disclosed |
| EP-2072524-A2 | Anti-inflammatory peptides | Salpep Biotechnology, Inc. (CA) | 2009-06-24 | — | — | EP | disclosed |
| US-20070054865-A1 | Anti-inflammatory peptides | AIM THERAPEUTICS INC. (CA) | 2007-03-08 | — | — | US | disclosed |
| US-20030229145-A1 | Pain treatment methods and compositions | GRUENENTHAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| US-20030195141-A1 | Anti-inflammatory peptides | AIM THERAPEUTICS INC. (CA) | 2003-10-16 | — | — | US | disclosed |
| WO-2003066670-A2 | DIPEPTIDES AND TRIPEPTIDES WITH ANTI-INFLAMMATORY ACTIVITY | SALPEP BIOTECHNOLOGY INC. (CA) | 2003-08-14 | — | — | WO | disclosed |
| EP-1326826-A1 | USE OF AMINO ACIDS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030871-A1 | USE OF AMINO ACIDS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229145-A1 | Pain treatment methods and compositions | AADAT, BCAT2, BCAT1 | SLC7A5 439/4885EPHX1 3424/4885SLC1A3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.